bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone339-499-9300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$54.58 million
Profitability
Miscellaneous
Employees764
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
bluebird bio (NASDAQ:BLUE) Frequently Asked Questions
What is bluebird bio's stock symbol?
bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."
How were bluebird bio's earnings last quarter?
bluebird bio Inc (NASDAQ:BLUE) released its quarterly earnings results on Thursday, August, 1st. The biotechnology company reported ($3.55) EPS for the quarter, missing the consensus estimate of ($3.04) by $0.51. The biotechnology company had revenue of $13.30 million for the quarter, compared to the consensus estimate of $13.13 million. bluebird bio had a negative return on equity of 35.90% and a negative net margin of 1,158.04%. The firm's revenue was up 68.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.91) EPS. View bluebird bio's Earnings History.
When is bluebird bio's next earnings date?
What price target have analysts set for BLUE?
19 equities research analysts have issued 12 month price objectives for bluebird bio's shares. Their predictions range from $104.00 to $195.00. On average, they anticipate bluebird bio's stock price to reach $148.59 in the next year. This suggests a possible upside of 68.6% from the stock's current price. View Analyst Price Targets for bluebird bio.
What is the consensus analysts' recommendation for bluebird bio?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 9 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for bluebird bio.
What are Wall Street analysts saying about bluebird bio stock?
Here are some recent quotes from research analysts about bluebird bio stock:
- 1. According to Zacks Investment Research, "bluebird reported wider-than-expected loss in the first quarter, while revenues beat estimates. The company has an impressive pipeline of gene therapies for genetic diseases and cancer. Zynteglo looks promising and a tentative approval in Europe is expected later this year. We are also positive about bluebird’s collaboration with Regeneron, as this provides the former with funds. The company is also developing CAR T therapies in collaboration with Celgene for myeloma. The CAR T market holds potential and the successful development of the candidates will benefit the company in the long run. However, competition is stiffening in this space. The company has no approved product in its portfolio yet and an unfavorable outcome from any of the ongoing studies will be detrimental. Shares have outperformed the industry in the past six months." (5/7/2019)
- 2. Cantor Fitzgerald analysts commented, "We rate bluebird bio Neutral. BLUE, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for rare severe genetic diseases. Its product candidates include Lenti-D, which is in a pivotal clinical study for the treatment of cerebral adrenoleukodystrophy; LentiGlobin, which is in Phase 1/2 clinical studies for the treatment of beta thalassemia major and severe sickle cell disease (SCD); and bb2121 and bb21217 CAR-T, candidates in multiple myeloma. Valuation Summary We value bluebird bio based on a risk-adjusted NPV calculation of its clinical pipeline." (12/3/2018)
Has bluebird bio been receiving favorable news coverage?
Media stories about BLUE stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. bluebird bio earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for bluebird bio.
Who are some of bluebird bio's key competitors?
Some companies that are related to bluebird bio include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Qiagen (QGEN), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Ablynx (ABLYF), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of bluebird bio own?
Who are bluebird bio's key executives?
bluebird bio's management team includes the folowing people:
- Mr. Nick Leschly, Pres, CEO & Director (Age 46)
- Mr. Jason F. Cole, Chief Operating & Legal Officer and Sec. (Age 46)
- Dr. Philip D. Gregory, Chief Scientific Officer (Age 48)
- Mr. Jeffrey T. Walsh, Chief Strategy Officer (Age 53)
- Dr. David M. Davidson, Chief Medical Officer (Age 55)
Who are bluebird bio's major shareholders?
bluebird bio's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Rothschild Investment Corp IL (0.02%). Company insiders that own bluebird bio stock include Alison Cecily Finger, David Davidson, James Mandell, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Mark Vachon, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Institutional Ownership Trends for bluebird bio.
Which institutional investors are selling bluebird bio stock?
BLUE stock was sold by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL. Company insiders that have sold bluebird bio company stock in the last year include David Davidson, Jason Cole, Jeffrey T Walsh, Kory James Wentworth, Nick Leschly, Philip D Gregory and Susanna Gatti High. View Insider Buying and Selling for bluebird bio.
How do I buy shares of bluebird bio?
Shares of BLUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is bluebird bio's stock price today?
One share of BLUE stock can currently be purchased for approximately $88.14.
How big of a company is bluebird bio?
bluebird bio has a market capitalization of $4.87 billion and generates $54.58 million in revenue each year. The biotechnology company earns $-555,630,000.00 in net income (profit) each year or ($10.68) on an earnings per share basis. bluebird bio employs 764 workers across the globe.View Additional Information About bluebird bio.
What is bluebird bio's official website?
How can I contact bluebird bio?
bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 339-499-9300 or via email at [email protected]
MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)
MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe BLUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
